Allink Biotherapeutics Secures $42M Series A
Allink Biotherapeutics, the ambitious newcomer to the biotechnology stage, has just secured a dazzling $42 million in Series A financing, underscoring its meteoric rise in the field of antibody therapeutics.
Spearheading this investment round was Lanchi Ventures, a global powerhouse known for championing early-stage breakthroughs.
Backing them was an impressive array of new investors, including Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment, along with existing heavyweights Gaorong Ventures and Med-Fine Capital.
This funding win isn't just another financial checkpoint for AllinkBio—it’s a turbo boost for a company that's already defying the usual speed limits of drug development.
“Since company inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage,” said Hui Feng, Ph.D., Founder and CEO.
With just a touch of modesty, Dr. Feng highlighted the crucial support from investors, both old and new, emphasizing their confidence in AllinkBio's ability to bridge cutting-edge science with real-world therapeutic solutions.
So, where’s this money headed?
Straight into the heart of innovation. The funds will fuel the global clinical development of its frontrunner candidates, ALK201 and ALK202, through Phase 1 trials spanning three continents—Australia, the United States, and China.
Alongside, the company is poised to bulk up its pipeline with fresh oncology and immunology assets while refining its proprietary bispecific antibody and ADC platforms.
If that sounds like a biotech version of a “go big or go home” strategy, you’re spot on.
Lanchi Ventures, the round’s lead investor, was quick to sing AllinkBio’s praises.
“AllinkBio’s exceptional execution speed and quality in advancing its lead program from preclinical to clinical stage, led by Dr. Feng, one of the leading figures in China’s biopharmaceutical industry, demonstrates the company’s high competitiveness in the field,” they noted.
That’s a mouthful of accolades, but given the company’s trajectory, it seems deserved.
AllinkBio’s innovative approach to ADC development, particularly in targeted oncology therapeutics, was another magnet for investor attention. It’s a space buzzing with potential, and the company’s rapid strides hint at its readiness to take a lead role.
Beyond the science, this round marks a pivotal moment for AllinkBio’s growth as a global player.
The company’s ambitious plans for international expansion signal not just confidence but a strategic intent to establish itself as a heavyweight on the world stage.
It’s a bold vision, but with $42 million now in its corner, the path seems more navigable than ever.
Founded in 2023, AllinkBio has made it clear that it’s not here to play small.
Its focus on creating first-in-class and best-in-class therapeutics in oncology and immunology has placed it squarely in the spotlight of a competitive field.
With its lead candidates heading for global trials and an expanding pipeline of promising assets, the company is not just chasing innovation; it’s setting a blistering pace.
For now, the biotech world watches as AllinkBio builds on this latest milestone.
If their current momentum is any indicator, we won’t have to wait long before they announce their next big leap forward.
Stay tuned—it’s bound to be an exciting ride.
